Lupin Ltd

BSE 500257 LUPIN INE326A01037

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 60 trading days

44 filings · 22 material · busiest 2026-07-08 and 2026-08-06

What it files

Press Release14 ESOP Allotment5 AGM / EGM4 Analyst / Investor Meet3 General2 Investor Presentation2 Acquisition2 Newspaper Publication2

Filings

44 in the window

25 August 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation of allotment of 30967 equity shares under ESOP.

Company Update / Allotment of ESOP / ESPS View filing →
24 August 2026

General

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

ESG Rating by ESG Risk Assessment and Insights Limited.

Company Update / General View filing →
20 August 2026

General

Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.

VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

Company Update / General View filing →
18 August 2026

KMP

Demise

Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

Company Update / Demise View filing →
17 August 2026

Press Release

Press Release / Media Release

Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.

Company Update / Press Release / Media Release View filing →
12 August 2026

Concall Transcript

Earnings Call Transcript

Transcript of Q1 FY2027 Earnings Conference Call

Company Update / Earnings Call Transcript View filing →
10 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation about participating in the Analyst/Institutional Investors Meet.

Company Update / Analyst / Investor Meet View filing →
10 August 2026

Press Release

Press Release / Media Release

Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.

Company Update / Press Release / Media Release View filing →
7 August 2026

Investor Presentation

Investor Presentation

Investor Presentation (Revised) - Q1 FY27 Results

Company Update / Investor Presentation View filing →
7 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Link of Audio recording of the Earnings Call-Q1 FY27.

Company Update / Analyst / Investor Meet View filing →
6 August 2026

Board Outcome

Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

Board Meeting / Outcome of Board Meeting View filing →
6 August 2026

Results

Board Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

Result / Financial Results View filing →
6 August 2026

Press Release

Press Release / Media Release

Lupin Q1 FY2027 Results

Company Update / Press Release / Media Release View filing →
6 August 2026

Investor Presentation

Investor Presentation

Investor Presentation- Q1 FY2027

Company Update / Investor Presentation View filing →
4 August 2026

AGM / EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.

AGM/EGM / AGM View filing →
4 August 2026

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer's Report.

AGM/EGM / AGM View filing →
31 July 2026

Press Release

Press Release / Media Release

Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.

Company Update / Press Release / Media Release View filing →
31 July 2026

Press Release

Press Release / Media Release

Lupin Announces the approval of Diazepam Injection, USP in the United States.

Company Update / Press Release / Media Release View filing →
22 July 2026

Board Meeting

Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Lupin Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....

Board Meeting / Board Meeting View filing →
22 July 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Schedule of Earnings Call for Q1 FY27

Company Update / Analyst / Investor Meet View filing →
21 July 2026

Acquisition

Acquisition

Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A.

Company Update / Acquisition View filing →
14 July 2026

Press Release

Press Release / Media Release

Lupin Recognized Among India's Best Employers in the Nation-Builders Category by Great Place to Work India 2026.

Company Update / Press Release / Media Release View filing →
14 July 2026

Newspaper Publication

Newspaper Publication

Copy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.

Company Update / Newspaper Publication View filing →
13 July 2026

AGM / EGM

Notice Of The Forty-Fourth Annual General Meeting Of The Company And Integrated Report For FY 2025-26.

Notice of the Forty-Fourth Annual General Meeting of the Company and Integrated Report for FY 2025-26.

AGM/EGM / AGM View filing →
13 July 2026

Annual Report

Reg. 34 (1) Annual Report.

Integrated Report of the Company for FY 2025-26.

Others / Reg. 34 (1) Annual Report View filing →
13 July 2026

BRSR

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Report of the Company for FY 2025-26.

Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
9 July 2026

Newspaper Publication

Newspaper Publication

Copy of Newspaper Advertisement relating to Annual General Meeting, Record Date and other related information.

Company Update / Newspaper Publication View filing →
8 July 2026

Compliance Certificate

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2026.

Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
8 July 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation of allotment of 2358 equity shares under ESOP.

Company Update / Allotment of ESOP / ESPS View filing →
8 July 2026

AGM / EGM

Intimation Of The Forty-Fourth Annual General Meeting.

Intimation of the Forty-Fourth Annual General Meeting to be held on Tuesday, August 04, 2026, at 04.00 p.m. (IST) through Video Conferencing/ Other Audio Visual Means.

AGM/EGM / AGM View filing →
8 July 2026

Record Date

Intimation Of Record Date For Payment Of Final Dividend.

Intimation of Record Date for payment of final Dividend.

Corp. Action / Record Date View filing →
6 July 2026

Press Release

Press Release / Media Release

Lupin Named Among World's Most Sustainable Companies by TIME and Statista.

Company Update / Press Release / Media Release View filing →
1 July 2026

Press Release

Press Release / Media Release

Lupin Announces EMA Approval for NaMuscla Expansion for Pediatric Indication with New Strengths.

Company Update / Press Release / Media Release View filing →
1 July 2026

Acquisition

Updates on Acquisition

Updates on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. ('MPPI'), a subsidiary company and Buyback of shares by MPPI.

Company Update / Acquisition View filing →
1 July 2026

Press Release

Press Release / Media Release

Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification.

Company Update / Press Release / Media Release View filing →
30 June 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation regarding Grant of 65,251 Stock Options under Lupin Employees Stock Option Scheme 2025.

Company Update / Allotment of ESOP / ESPS View filing →
26 June 2026

Press Release

Press Release / Media Release

Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets.

Company Update / Press Release / Media Release View filing →
26 June 2026

Trading Window

Closure of Trading Window

Intimation of Closure of Trading Window.

Insider Trading / SAST / Closure of Trading Window View filing →
22 June 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation regarding Grant of 1567591 Stock Option under Lupin Employees Stock Option Scheme 2025.

Company Update / Allotment of ESOP / ESPS View filing →
17 June 2026

Press Release

Press Release / Media Release

Lupin Launches Azilsartan Medoxomil Tablets in the United States.

Company Update / Press Release / Media Release View filing →
8 June 2026

Press Release

Press Release / Media Release

Lupin Collaborates with ERN for Luforbec (beclometasone/formoterol) pMDI Launch in Spain.

Company Update / Press Release / Media Release View filing →
4 June 2026

Press Release

Press Release / Media Release

Lupin Receives Approval from U.S. FDA for Ranluspec (Ranibizumab) Injection

Company Update / Press Release / Media Release View filing →
3 June 2026

Press Release

Press Release / Media Release

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection.

Company Update / Press Release / Media Release View filing →
3 June 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation of allotment of 16673 equity shares under ESOP.

Company Update / Allotment of ESOP / ESPS View filing →